These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16028009)

  • 1. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.
    Ng CM; Joshi A; Dedrick RL; Garovoy MR; Bauer RJ
    Pharm Res; 2005 Jul; 22(7):1088-100. PubMed ID: 16028009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab.
    Wu B; Joshi A; Ren S; Ng C
    J Pharm Sci; 2006 Jun; 95(6):1258-68. PubMed ID: 16637054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis.
    Mortensen DL; Walicke PA; Wang X; Kwon P; Kuebler P; Gottlieb AB; Krueger JG; Leonardi C; Miller B; Joshi A
    J Clin Pharmacol; 2005 Mar; 45(3):286-98. PubMed ID: 15703364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
    Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
    Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
    Bonnekoh B; Böckelmann R; Pommer AJ; Malykh Y; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(2):96-111. PubMed ID: 17167274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
    Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
    J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
    Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
    Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
    N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
    Guttman-Yassky E; Vugmeyster Y; Lowes MA; Chamian F; Kikuchi T; Kagen M; Gilleaudeau P; Lee E; Hunte B; Howell K; Dummer W; Bodary SC; Krueger JG
    J Invest Dermatol; 2008 May; 128(5):1182-91. PubMed ID: 18239614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
    Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
    Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efalizumab modulates T cell function both in vivo and in vitro.
    Koszik F; Stary G; Selenko-Gebauer N; Stingl G
    J Dermatol Sci; 2010 Dec; 60(3):159-66. PubMed ID: 21044829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.
    Chetty M; Li L; Rose R; Machavaram K; Jamei M; Rostami-Hodjegan A; Gardner I
    Front Immunol; 2014; 5():670. PubMed ID: 25601866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.
    Lowes MA; Chamian F; Abello MV; Leonardi C; Dummer W; Papp K; Krueger JG
    BMC Dermatol; 2007 Feb; 7():2. PubMed ID: 17324275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy.
    Bonnekoh B; Malykh Y; Böckelmann R; Bartsch S; Pommer AJ; Gollnick H
    Eur J Dermatol; 2006; 16(6):623-35. PubMed ID: 17229602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
    Schön MP
    Clin Dermatol; 2008; 26(5):509-14. PubMed ID: 18755369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells.
    Coffey GP; Stefanich E; Palmieri S; Eckert R; Padilla-Eagar J; Fielder PJ; Pippig S
    J Pharmacol Exp Ther; 2004 Sep; 310(3):896-904. PubMed ID: 15190122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efalizumab.
    Chacko M; Weinberg JM
    Dermatol Ther; 2007; 20(4):265-9. PubMed ID: 17970891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.